Linde Reports Third-Quarter 2020 Results (Earnings Release Tables attached)

unigraphique.com
LOS ANGELES, CA / ACCESSWIRE / June 4, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against CytomX Therapeutics, Inc. (CytomX or the Company) (NASDAQ: CTMX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Companys securities between May 17, 2018 and May 13, 2020, inclusive (the Class Period) are encouraged to contact the firm before July 20, 2020. If you are a shareholder who suffered a loss, click here to participate . We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firms website at www.schallfirm.com , or by email at brian@schallfirm.com . The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. CytomX minimized problems with its drug candidate CX-072s efficacy, as documented in its PROCLAIM-CX-072 clinical program. The Company also downplayed CX-2009s efficacy and safety problems, as observed in the PROCLAIM-CX-2009 clinical program. Based on these facts, the Companys public statements were false and materially misleading throughout the class period. When the market learned the truth about CytomX, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law Firm Brian Schall, Esq., www.schallfirm.com Office: 310-301-3335 info@schallfirm.com SOURCE: The Schall Law Firm View source version on accesswire.com: https://www.accesswire.com/592805/SHAREHOLDER-ACTION-ALERT-The-Schall-Law-Firm-Announces-the-Filing-of-a-Class-Action-Lawsuit-Against-CytomX-Therapeutics-Inc-and-Encourages-Investors-with-Losses-in-Excess-of-100000-to-Contact-the-Firm View comments
Health Experts Share Their Strategies for Staying Safe During Delta
Health professionals discuss their approaches to safety amid Delta's resurgence, including travel and social activities.